Status:
COMPLETED
Diagnostic Accuracy of the MADx Multi Array Xplorer (MAX 45k) Automated Laboratory System and the MADx Allergy Explorer Version 2 (ALEX²) - IgE Multiplex Test for the Diagnosis of Pre-defined Groups of Specific High-priority Allergens
Lead Sponsor:
MacroArray Diagnostics GmbH
Conditions:
Birch Pollen Allergy
Grass Pollen Allergy
Eligibility:
All Genders
Up to 100 years
Phase:
NA
Brief Summary
About 20% of the general population are affected by an allergy - with an upward trend. Quite often, allergic people do not consider their disease as serious and suffer from subsequent complications, l...
Eligibility Criteria
Inclusion
- Male and female subjects with suspicion of allergy
- Written consent of the participant (and/or his/her parent or legal representative) after being informed
Exclusion
- Oral treatment with corticosteroids (\>5mg/day)
- Treatment with antihistamines (histamine (H1) receptor blockers)
- Hematological disease (coagulation disorders, anemia)
Key Trial Info
Start Date :
July 22 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 12 2022
Estimated Enrollment :
839 Patients enrolled
Trial Details
Trial ID
NCT04435678
Start Date
July 22 2020
End Date
April 12 2022
Last Update
April 22 2022
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Dermatology and Venerology, Medical University of Graz
Graz, Austria, 8036
2
Allergy Outpatient Clinic Reumannplatz
Vienna, Austria, 1100